,%20Director,%20IIT%20Madras,%20&%20R.%20Meenakumari,%20Director,%20NIS,%20sign%20MoU%20in%20the%20presence%20of%20Ravindra%20Gettu,%20IIT-M.jpg)
The partnership is expected to result in development of new collaborative teaching programmes and research in the areas of clinical research, molecular biology and in-vitro cell line studies and health system research besides in exchange of faculty members.
An MoU in this regard was signed recently by V Kamakoti, Director, IIT-Madras, and R Meenakumari, Director, NIS.
To establish a scientific basis
Siddha is an important school of Indian medicine. This collaboration will focus on establishing a scientific basis that explains the efficacy of Siddha medicines, said Kamakoti.
The institutes will also jointly organise seminars, workshops, webinars, conferences, continuing education programmes [including Continuing Medical Education (CME)] and develop academic programmes. They will also promote the exchange of students, PhD, postdoctoral scholars and faculty for teaching/training programmes.
Meenakumari said, “We hope that the collaboration will open new avenues for knowledge sharing about the tremendous therapeutic potential of available Siddha medicine and the application of cutting-edge technology of IIT-M in scientific validation of Siddha formulations, identification of its bioactive molecule and mechanism of action.”
Published on
August 05, 2022
,%20Director,%20IIT%20Madras,%20&%20R.%20Meenakumari,%20Director,%20NIS,%20sign%20MoU%20in%20the%20presence%20of%20Ravindra%20Gettu,%20IIT-M.jpg&description=IIT-Madras+to+collaborate+with+National+Institute+of+Siddha){kind=link}